Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0V0BO
|
||||
Former ID |
DCL001144
|
||||
Drug Name |
Anti-FGFR3
|
||||
Drug Type |
Antibody
|
||||
Indication | Multiple myeloma [ICD9: 203; ICD10:C90] | Phase 1 | [1] | ||
Company |
Genentech
|
||||
Target and Pathway | |||||
Target(s) | FGF-3 receptor | Target Info | [1] | ||
KEGG Pathway | MAPK signaling pathway | ||||
Ras signaling pathway | |||||
Rap1 signaling pathway | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
Signaling pathways regulating pluripotency of stem cells | |||||
Regulation of actin cytoskeleton | |||||
Pathways in cancer | |||||
MicroRNAs in cancer | |||||
Bladder cancer | |||||
Central carbon metabolism in cancer | |||||
PANTHER Pathway | FGF signaling pathway | ||||
Reactome | FGFR3 mutant receptor activation | ||||
WikiPathways | Regulation of Actin Cytoskeleton | ||||
Endochondral Ossification | |||||
Bladder Cancer | |||||
Neural Crest Differentiation | |||||
Signaling by FGFR | |||||
References | |||||
REF 1 | Clinical pipeline report, company report or official report of Genentech (2011). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.